Poul la Cour

First Sentier Investors (UK) IM Ltd. (FSIIM) is the wholly-owned, Great Britain-based specialist asset management subsidiary of S.I. Holdings Ltd., ultimately held by Mitsubishi UFJ Financial Group, Inc. (TYO: 8306) in Japan. Headquartered in Edinburgh, the firm was founded in 1970 and formerly known as First State Investment Management (UK) Ltd. FSIIM provides discretionary investment management and portfolio management services to a range of institutional clients and funds.

Columbia Threadneedle (EM) Investments Ltd. (Columbia Threadneedle EMI) is a specialist fund management firm headquartered in London, UK. The firm was founded in 1995 and formerly known as LGM Investments Ltd. In 2021, they became a wholly owned subsidiary of Columbia Threadneedle Investments UK International Ltd., which is owned by Ameriprise Financial, Inc. (NYSE: AMP) in the US. The legal entity of LGM Investments Ltd. became Columbia Threadneedle (EM) Investments Ltd. in 2022. Columbia Threadneedle EMI provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients around the world.

Nykredit Bank A/S (Investment Management) (Nykredit IM) is the investment management division of Nykredit Bank A/S, ultimately held by Forengin Nykredit in Denmark. The firm was founded in 1851 and changed their name to Nykredit in 1985 when Forenede Kreditforeninger and Jyllands Kreditforening merged. Nykredit IM is headquartered in Copenhagen and provides securities management, deposit and loan products, financial instruments and asset management services for individual, corporate and commercial clients.

Skagen AS (Investment Management) (Skagen-IM) is the investment management division of Skagen AS, itself a subsidiary of Storebrand ASA (OSE: STB, FRA: SKT) in Norway. The firm was founded in 1993 by Kristoffer Stensrud, Tor Dagfinn Veen and Åge Westbø. Headquartered in Stavanger, Skagen-IM manages Skagen global equity and fixed income funds for individual and institutional investors. They are a socially responsible investor.

Danmarks Skibskredit A/S engages in the provision of loans for shipping companies. It offers financing against a first mortgage in ships and of shipowner's payment of installments to a shipyard. The company was founded on June 6, 1961 and is headquartered in Copenhagen, Denmark.

Svenska Handelsbanken AB (Broker) (Handelsbanken-Broker) is the broker/dealer division of Svenska Handelsbanken AB (STO: SHB-A; OTCMKTS: SVNLY) in Sweden. Headquartered in Stockholm, Handelsbanken-Broker was founded in 1871 and provides trading services to large corporates. The firm trades in equities, money market instruments, currencies, commodities and derivatives.

Nykredit Realkredit A/S engages in the provision of financial services. It offers banking, mortgage lending, insurance, investment, pension expertise, and estate agency business. The company was founded in 1851 and is headquartered in Copenhagen, Denmark.

7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark.

Lån & Spar Bank A/S (Investment Management) (Lån & Spar IM) is the investment management division of Lån & Spar Bank A/S (CSE: LASP) in Denmark. Established in 1986, the firm is based in Copenhagen and provides investment management services primarily for pension funds, corporations, foundations and municipalities. They also offer discretionary portfolio management services to high-net worth individuals.

Redalpine Venture Parners AG (Redalpine) is an independent venture capital investment firm headquartered in Zurich, Switzerland. The firm was founded in 2006.

BLS Capital Fondsmæglerselskab A/S (BLS Capital) is an asset management firm and investment adviser headquartered in Klampenborg, Denmark. The firm was founded in 2008 by Peter Bundgaard, Anders Lund and Erik Mortensen. They are a subsidiary of BLS Finans A/S. BLS Capital serves as the investment adviser to a Danish and US Fund as well as segregated accounts on behalf of US institutions.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

Indi Molecular, Inc. is a life sciences company that develops a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. It offers products used by physicians and patients to manage complex and serious diseases like cancer, diabetes, and Alzheimer's. The company was founded by Michael Phelps, Albert A. Luderer, Leroy E. Hood, and Jim Heath in 2013 and is headquartered in Culver City, CA.

IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark.

NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark.

Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands.

Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark.

AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark.

SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA.

CytoKi Pharma ApS engages in the research and experimental development within biotechnology. It develops therapeutics for serious tissue and organ injuries. The company was founded by Rasmus Jørgensen on June 12, 2019 and is headquartered in Vaerlose, Denmark.